Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Novo Nordisk, a Pharma Player in the Sweet Spot of an 'Endless' Market


One of the leading pharmaceutical companies in the world hardly gets the exposure it deserves.


Novo Nordisk (NVO), a Danish pharmaceutical company that focuses on diabetes care and biopharmaceuticals, is a quiet giant, employing 30,000 people in 76 countries.

I find the short- and long-term investment case for Novo Nordisk as compelling as any idea out there. Here's why.

More than 200 million people worldwide suffer from some form of diabetes. Patients with Type 1 (juvenile) diabetes can't make insulin at all and need to inject it their whole lives.

Type 2 diabetes - the kind you get from eating too much and not exercising - now is much more common. Today, more than 26 million Americans have diabetes, and another 79 million have pre-diabetes.

Experts calculate that by 2050, one in three American adults will suffer from the full-blown disease. And as China, India, and the rest of the emerging world adopt Western lifestyles and diets, diabetes is surging there, as well.

No wonder that the treatment of diabetes through insulin has emerged as one of the world's great growth stories. Worldwide insulin sales have quadrupled in the last decade, to $15.4 billion.

As diabetes specialist David Nathan of Massachusetts General Hospital observed, "The market for insulin is almost endless. It is going up and up and up. It is not even close to the peak."

Today, Novo Nordisk is the world's largest insulin maker with a 50% share of the global market. Equally importantly, it has a strong research and development (R&D) pipeline of future products to treat diabetes to keep its competitors at bay.

Novo Nordisk recently filed for approval of its new drugs Degludec and DegludecPlus. It has another drug for Type 2 diabetes, IDegLira, in Phase 3. Five other drugs for Type 2 diabetes are in earlier stages of the R&D pipeline.

All of these add up to terrific prospects for Novo Nordisk in the years ahead. So buy Novo Nordisk at market and set your stop at $128.

Editor's Note: This article was written by Nicholas Vardy of Bull Market Alert.

Below, find some more great investing and trading content from MoneyShow:

The Price of Morality Investing
By Matthew Delman

Where Does Apple Go From Here?
By Jim Trippon

Election Year Dangers for Income Investors
By Roger Conrad

A Hot New Fashion Retailer
By Michael Cintolo

Twitter: @TopProsTopPicks
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos